<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02675049</url>
  </required_header>
  <id_info>
    <org_study_id>MA10</org_study_id>
    <nct_id>NCT02675049</nct_id>
  </id_info>
  <brief_title>Efficacy and Optimal Dose Selection of Intranasal Dexmedetomidine During Breast Lumpectomy Under Local Anaesthesia</brief_title>
  <official_title>Efficacy and Optimal Dose Selection of Intranasal Dexmedetomidine During Breast Lumpectomy Under Local Anaesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is going to evaluate the safety and effectiveness of intranasal
      DEX(dexmedetomidine) in breast lumpectomy under local anaesthesia,and to investigate the
      optimal dose of intranasal DEX in breast lumpectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Breast lumpectomy associated with a high level of anxiety, fear and pain requires fast and
      effective anaesthesia techniques. Presently, this procedure is usually performed under
      general or local anaesthesia. General anaesthesia provides an effective sedation; however,
      for minor procedures, general anaesthesia is resource-intensive and postoperative
      complications, such as nausea, vomiting or extended time to ambulation, are more likely.
      Local anaesthesia alone may be uncomfortable or uncooperative for patients. Therefore, an
      efficient drug regimen is required that reduces analgesic consumption, minimises
      opioid-related side effects and shortens post-anaesthesia care unit (PACU) stay following
      surgery.

      Dexmedetomidine (DEX) is a highly selective α2 adrenoreceptor agonist that provides sedation
      without respiratory depression. Its sedative, anxiolytic, analgesic and haemodynamic effects
      have made it a useful adjunct to anaesthesia and sedation. DEX may provide a conscious
      sedation under monitored anaesthesia care (MAC) that is a logical middle ground between
      general anaesthesia and local anaesthesia. Intranasal DEX was recently shown to provide
      satisfactory anaesthesia and premedication sedation in healthy volunteers and paediatric
      patients. The intranasal route is not only effective, but also well-tolerated and convenient
      This trial is going to evaluate the safety and effectiveness of intranasal
      DEX(dexmedetomidine) in breast lumpectomy under local anaesthesia, and to investigate the
      optimal dose of intranasal DEX in breast lumpectomy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sedation changes using the modified Observer's Assessment of Alertness/Sedation (OAA/S) scale</measure>
    <time_frame>before surgery,during surgery and after surgery for sedation changes，assessed up to 2 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>pain scores changes by pain NRS scores</measure>
    <time_frame>before surgery,during surgery and after surgery for pain scores，assessed up to 2 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse event that is related to treatment:severe sinus bradycardia</measure>
    <time_frame>perioperative period</time_frame>
    <description>bradycardia (defined as HR &lt; 50 bpm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event that is related to treatment:hypotension</measure>
    <time_frame>perioperative period</time_frame>
    <description>hypotension (defined as SBP &lt; 90 mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event that is related to treatment:nausea and vomiting</measure>
    <time_frame>perioperative period</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Intranasal Dexmedetomidine Breast Cancer Local Anaesthesia</condition>
  <arm_group>
    <arm_group_label>0.9% saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients were assigned to receive 0.9% saline intranasally 45 min before surgery using a computer-generated random number table.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dexmedetomidine 1 µg.kg-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients were assigned to receive 1µg.kg-1dexmedetomidine intranasally 45 min before surgery using a computer-generated random number table.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dexmedetomidine 1.5 µg.kg-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients were assigned to receive 1.5µg.kg-1 dexmedetomidine intranasally 45 min before surgery using a computer-generated random number table.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dexmedetomidine 2 µg.kg-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients were assigned to receive 2µg.kg-1 dexmedetomidine intranasally 45 min before surgery using a computer-generated random number table.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% saline</intervention_name>
    <description>0.9% saline intranasally 45 min before surgery using a computer-generated random number table.</description>
    <arm_group_label>0.9% saline</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexmedetomidine 1µg.kg-1</intervention_name>
    <description>dexmedetomidine 1µg.kg-1 intranasally 45 min before surgery using a computer-generated random number table.</description>
    <arm_group_label>dexmedetomidine 1 µg.kg-1</arm_group_label>
    <other_name>Ai Bei Ning1 µg.kg-1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexmedetomidine 1.5µg.kg-1</intervention_name>
    <description>Dexmedetomidine 1.5µg.kg-1 intranasally 45 min before surgery using a computer-generated random number table.</description>
    <arm_group_label>dexmedetomidine 1.5 µg.kg-1</arm_group_label>
    <other_name>Ai Bei Ning1 µg.kg-1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine 2µg.kg-1</intervention_name>
    <description>dexmedetomidine 2µg.kg-1 intranasally 45 min before surgery using a computer-generated random number table.</description>
    <arm_group_label>dexmedetomidine 2 µg.kg-1</arm_group_label>
    <other_name>Ai Bei Ning 2µg.kg-1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  with ASA(American Society of Anesthesiologists) physical status I and II

          -  scheduled for breast lumpectomy

        Exclusion Criteria:

          -  a history of heart block

          -  upper respiratory tract infection

          -  asthma

          -  allergy to DEX or local anaesthetics

          -  memory or cognitive dysfunction

          -  pregnancy

          -  lack of understanding the consent process

          -  impaired liver or renal function

          -  a history of drug or alcohol abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2016</study_first_submitted>
  <study_first_submitted_qc>February 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2016</study_first_posted>
  <last_update_submitted>February 29, 2016</last_update_submitted>
  <last_update_submitted_qc>February 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intranasal</keyword>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Anaesthesia</keyword>
  <keyword>Breast Lumpectomy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

